Introduction
Hereditary leiomyomatosis and renal cell carcinoma syndrome is an autosomal dominant syndrome induced by germline mutations of the fumarate hydratase (FH) gene located on chromosome 1q42.3 [1] . This gene codes for the enzyme fumarate hydratase, or fumarase, which catabolizes fumarate into malate in the tricarboxylic acid cycle. When FH activity is impaired, the consequent accumulation of fumarate acts as an oncometabolite and as an epigenetic modifier [2] . Several mechanisms of carcinogenesis may contribute to hereditary leiomyomatosis and renal cell carcinoma tumor development, such as inhibition of hypoxiainducible factor prolyl hydroxylase enzymes that results in hypoxia-inducible factor upregulation [3] , changes in glycogen and lipid metabolism [4] , and aberrant succination [5] .
Loss of FH is associated with an epithelial-tomesenchymal transition, a phenotypic switch associated with cancer initiation which may explain why hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma are high-grade tumors, and why they often and rapidly metastasize [2, 6, 7] .
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma are a distinct entity in both 2012 International Society of Urological Pathology (ISUP) and 2016 World Health Organization (WHO) classifications [8, 9] . According to these classifications, the disctinctive feature of these tumors is a prominent eosinophilic macronucleolus, which represents an actively synthesizing cell [10] with a perinucleolar clear halo (i.e., an inclusion-like nucleolus) [6, 11] . From an immunohistochemistry perspective, tumors are often FHnegative and S-(2-succino)-cysteine (2SC) positive. As a consequence of FH gene mutation and loss of function, staining for FH protein expression is often lost. 2SC production is directly linked to FH inactivation and increased levels of intracellular fumarate [7, 12, 13 ]. An increase in the level of intracellular fumarate results in its spontaneous reaction with the cysteine residues of many proteins, thereby causing succination and 2SC accumulation. FH antibody is widely available, and is commonly used to confirm post hoc that a renal cell carcinoma in a FH mutation carrier is indeed associated with the hereditary leiomyomatosis and renal cell carcinoma predisposition syndrome. As of 2SC, its limited availability means immunohistochemistry is mainly done in a research context. Until recently, type 2 papillary renal cell carcinoma was the only renal cell carcinoma type associated with hereditary leiomyomatosis and renal cell carcinoma [1, 14, 15] . It is now known that papillary renal cell carcinoma of unspecified type, collecting duct carcinoma, tubulocystic carcinoma, and unclassified renal cell carcinoma are also seen [7, 16, 17] . These observations, mainly published in the past 2-3 years, have undeniably added to the complexity of hereditary leiomyomatosis and renal cell carcinoma, whereas knowledge of the syndrome among urologists, oncologists, and pathologists has not increased accordingly. Considering the benefits of identifying a FH mutation in a patient with renal cell carcinoma, i.e., targeted testing in relatives and yearly renal cell carcinoma screening with magnetic resonance imaging in carriers, complementary easy-to-implement tests in addition to the pathologist's expertise and attention to characteristic hereditary leiomyomatosis and renal cell carcinoma features, would ensure that all patients with suspected hereditary leiomyomatosis and renal cell carcinoma are appropriately referred to cancer genetics clinics and tested for FH germline mutations.
We studied two groups of renal cell carcinomas: 24 renal cell carcinomas from proven mutations carriers and 12 type 2 papillary renal cell carcinomas from patients without FH mutations. We compared their pathological features and assessed more specifically whether characteristics deemed distinctive of hereditary leiomyomatosis and renal cell carcinoma are indeed exclusively seen in tumors from mutation carriers. We also calculated the sensitivity and specificity of FH/2SC immunohistochemistries and association of both in predicting a patient's genetic status. This study complements a previous publication reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma [16] .
Materials and methods

Patients
Renal cell carcinoma from FH germline mutations carriers, and papillary renal cell carcinoma type 2 from patients who had been tested negatively for mutation of FH were identified through the National Cancer Institute (INCa) "Inherited Predisposition to Kidney Cancer" database located at the Kremlin-Bicêtre PREDIR Centre. In most cases, detailed clinical and pathological reports were obtained from the PREDIR database. For the remaining cases, data were collected either by the physicians who prescribed the FH genetic testing or by review of the institutional records.
We contacted each pathologist involved in order to get a representative tissue block of the renal neoplasm. In keeping with legal requirements, written consent for genetic testing had been obtained from all of the patients.
Genetic testing and evaluation of FH mutations
FH germline genetic testing was performed in the Gustave Roussy Cancer Genetics Laboratory (Villejuif). Mutations and large rearrangements were identified using Sanger sequencing complemented by multiplex ligation probedependent amplification for the most recent cases. With the exception of three first degree relatives from proven hereditary leiomyomatosis and renal cell carcinoma families who died from metastatic renal cell carcinoma before genetic testing could take place, all of our patients underwent FH mutation analysis. These three cases were considered obligatory carriers.
All frameshift mutations, nonsense mutations, and large deletions were considered deleterious. For other types of genetic alterations (e.g., missense and splice-site mutations), assessment of FH enzyme activity was performed using spectrophotometry [18] . An enzymatic activity of ≤78% reflects loss of FH function [19] . If FH activity could not be measured, information taken from the LOVD database was used as a reference (http://databases.lovd.nl/shared/variants/ FH/unique).
Tumor analysis
An uropathologist (SF) reviewed all tumors, and compiled the following pathological features: architectural pattern, Internal Society of Urological Pathology (ISUP) grade, pTN stage, and the presence or not of prominent macronucleoli and a perinucleolar clear halo. A perinucleolar halo was defined as an entirely clear area (i.e., devoid of any chromatin) between the nucleus and the cytoplasm as seen by microscopy at high magnification. The ISUP grade and the TNM classification were evaluated according to the most recent ISUP/World Health Organization (WHO)/American Joint Committee on Cancer (AJCC) classifications [8] .
Immunohistochemistry
Immunostaining for FH and 2SC was performed on formalin-fixed paraffin embedded sections in two different French laboratories (i.e., the Department of Pathology of Bicêtre Hospital and the Anatomical Pathology Laboratory of the Gustave Roussy Institute, Campus Cancer Grand Paris, Villejuif), and they were scored independently by two pathologists in a single-blind manner (SF and CG). We used a commercially available primary anti-FH mouse monoclonal antibody (1:1000 dilution, clone J-13, reference sc-100743, Santa Cruz Biotechnology) with an automated staining platform (Leica Bond III Autostainer, Leica Biosystems) at the Bicêtre Hospital. Anti-2SC rabbit polyclonal antibody was kindly provided by Dr Norma Frizzell (University of South Carolina, USA), and it was used at a 1:5000 dilution. Automated staining with the 2SC antibody was performed with a BenchMark ULTRA system (Roche/ Ventana Biosystems). FH-negative staining in tumor cells was considered negative in the presence of an internal positive control in inflammatory or stromal cells, or when FH-positive staining in the non-tumoral kidney parenchyma was obvious. 2SC-positive staining was considered positive when there was 2SC-negative staining in the adjacent nonneoplastic cells (i.e., an internal negative control). For each case, cytoplasmic staining was assessed as being either absent (negative) or present (positive).
For tumors with a peculiar architectural pattern, staining with additional antibodies was performed in order to establish the histological type according to the 2016 WHO classification. The following antibodies were used: anti-vimentin (Clone V9, Dako, at 1:100 dilution), anti-CD10 (Clone 56C6, Leica, at 1:200 dilution), anti-P504S (Polyclonal, Biocare, ready to use), anti-cytokeratin 7 (CK7) (Clone OV-TL 12/30, Dako, at 1:100 dilution), anti-CA9 (Polyclonal, Novusbio, 1:800), and anti-TFE3 (Polyclonal, tebu-bio, 1:800).
Statistical analysis
Statistical analyses were performed in regard to the sensitivity and specificity of the following strategies: presence of a clear perinucleolar halo, FH− or 2SC+ immunostaining, and combined FH−/2SC+ immunohistochemistries. The sensitivity of each strategy corresponds to the number of positive cases according to this strategy out of the 24 renal cell carcinomas from proven mutations carriers. The specificity of each strategy corresponds to the number of negative cases according to this strategy out of the 12 papillary renal cell carcinomas from patients without FH mutations. Comparison of sensitivities between combined FH−/2SC+ immunohistochemistries and anti-FH immunostaining was performed with a Mac Nemar test by comparing the proportion of positive cases for each strategy among the 24 renal tumors from proven mutations carriers. The threshold for statistical significance was set to p < 0.05. Statistical analysis was performed using SAS software (SAS Institute Inc., Cary, NC).
Results
Renal cell carcinoma in FH mutation carriers
We identified 42 hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas in 39 FH mutation carriers, and obtained tissue blocks for 24 renal cell carcinomas from 23 patients. Out of these 24 tumors, 23 were included in our latest publication, which had a mainly clinical focus, did not include an in-depth pathology exploration of tumors, and above all did not compare renal cell carcinoma in carriers with type 2 papillary renal cell carcinoma in proven non-carriers [16] . The 23 renal cell carcinomas had been classified according to their primary pathological feature, but secondary components were not detailed. A majority of renal cell carcinomas were papillary type 2 (n = 13). There were also papillary renal cell carcinomas of unspecified type (non-type 1, non-type 2, n = 4), unclassified carcinoma (n = 3), tubulocystic carcinoma (n = 2), and one collecting carcinoma. A 29-year-old woman with hereditary leiomyomatosis and renal cell carcinoma has since been diagnosed with type 2 papillary renal cell carcinoma, and was therefore included in this study.
When reviewing tissue blocks, we observed prominent eosinophilic nucleoli with a perinucleolar halo in 23/24 renal cell carcinomas (96%, Table 1 ). These nuclear characteristics were observed either in many of the tumor cells or sometimes only in a small fraction of the cells, even at small magnification (Fig. 1) . Most renal cell carcinomas displayed a complex architecture with multiple pathological patterns. Eighteen renal cell carcinomas had at least two components, and ten had three components or more. In addition to the patterns reported previously by our group (e.g., papillary, tubulopapillary, tubulocystic), cribriform, sarcomatoid, and rhabdoid components were also observed in 13 cases (Table 2 ; Fig. 2a-d) . Multiplicity of components and sarcomatoid/rhabdoid features were seen across the spectrum of hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma, regardless of the primary type (type 2 papillary renal cell carcinoma vs. other).
FH immunohistochemistry was negative in 21 renal cell carcinoma, and positive in three (Table 1) . 2SC immunohistochemistry was positive in 22 renal cell carcinomas and negative in two (Fig. 3a, b) . Overall, 19 renal cell carcinomas were FH−/2SC+, three were 2SC+/FH+ and two were 2SC−/FH− (Tables 3 and 4) .
Interestingly, three benign unilocular cysts were observed in one patient. Lining cells exhibited strong 2SC staining and FH-expression loss (Fig. 4a-c) .
Renal cell carcinoma in FH wild-type patients
Twelve type 2 papillary renal cell carcinomas from individuals with no germline FH mutation were reviewed. Prominent clear perinucleolar halos were observed in 7/12 cases (58%) (Fig. 5a, b) . Pathological patterns were few, and consisted only of papillary, tubular, and solid components (Table 5) . Only one renal cell carcinoma displayed all three patterns. Aggressive sarcomatoid or rhabdoid features were absent. All renal cell carcinomas were FH-positive on immunohistochemistry, and all but one were 2SC-negative (Tables 1 and 4 ). Table 1 Sensitivity of negative anti-FH immunohistochemistry was 87.5% (21/24) and specificity was 100% (12/12). For positive anti-2SC immunohistochemistry, sensitivity and specificity were 91.7% (22/24) and 91.7% (11/12), respectively. Combined FH−/2SC+ immunohistochemistry had 100% sensitivity (24/24), i.e., all tumors were FH−, 2SC+ or both, and 91.7% specificity (11/12) . This combination seems to improve the sensitivity of the test compared to anti-FH only immunostaining (without reaching the statistical significance, p = 0.083).
Sensitivity and specificity of FH/2SC immunohistochemistries
Discussion
On the basis of our comparison of renal cell carcinoma in FH mutation carriers and in wild type patients, we conclude that multiplicity of architectural patterns, rhabdoid/sarcomatoid components and FH/2SC staining, but not CI confidence interval a The combinaison of negative FH and positive 2SC immunohistochemistries was considered as positive prominent eosinophilic nucleoli with perinucleolar halos, differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma from type 2 papillary renal cell carcinoma without FH alteration. To our knowledge, this is the first time that a formal comparison between proven hereditary leiomyomatosis and renal cell carcinoma patients and individuals tested negative for FH germline mutations is done. Our most unexpected finding was the presence of prominent eosinophilic nucleoli with perinucleolar halos in 58% of type 2 papillary renal cell carcinomas from patients not carrying FH germline mutations. Indeed, this feature is distinctive of hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma in both ISUP and WHO kidney tumors classifications [8] . More precisely, pathologists who observe it are expected to conclude in their report that the patient is likely to have hereditary leiomyomatosis and renal cell carcinoma. We would therefore urge caution against premature conclusions, given the anxiety such a genetic diagnosis could trigger in patients and their relatives. We would also suggest future versions of kidney tumor classifications put less emphasis on these prominent nucleoli and halos in diagnosing hereditary leiomyomatosis and renal cell carcinoma, as this is apparently a sensitive, but not very specific feature of the syndrome. We did observe it in most (23/24) hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas. Admittedly, the twelve wild type cases had been referred for germline testing because clinical and pathological features, prominent nucleoli with halos included, suggested hereditary leiomyomatosis and renal cell carcinoma, and this might have led to selection bias. The ideal control group would have been large consecutive institutional, non-referral case series of type 2 papillary renal cell carcinoma and renal cell carcinoma with rare or complex histologies, with subsequent negative FH mutational germline testing. Considering the benefits of identifying a FH mutation in a patient with renal cell carcinoma, complementary easy-toimplement tests in addition to the pathologist's expertise, would ensure that all patients with suspected hereditary leiomyomatosis and renal cell carcinoma are appropriately referred to cancer genetics clinics and tested for FH germline mutations. We have demonstrated the limits of prominent nucleoli and adjacent halos in predicting a patient's genetic status. According to our results, the multiplicity and variety of patterns, and FH/2SC immunohistochemistry are much more informative in identifying hereditary leiomyomatosis and renal cell carcinoma patients. Not only did we see that the vast majority of renal cell carcinoma in carriers contained multiple components, we also observed sarcomatoid or rhabdoid patterns in eight tumors, reflecting the aggressive behavior of hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma [20] . These features were absent in non-carriers, although cannot exclude the possibility that a review of a larger number of tissue blocks would have shown more pattern diversity. All hereditary leiomyomatosis and renal cell carcinomaassociated renal cell carcinomas were either FH− or 2SC +, and the sensitivity of combined immunohistochemistry was therefore 100%, higher than FH immunohistochemistry only. The use of both antibodies is thus necessary to identify all mutation carriers. We acknowledge the limited availability of anti-2SC antibody, and the fact that it has mainly been used in in a research context so far. There is, however, obvious commercial interest in marketing such an antibody considering its use not only in renal cell carcinoma but also in both uterine and cutaneous leiomyomas [13, 21] Trpkov et al. [7] performed FH/2SC immunohistochemistry on a large series of renal cell carcinomas. They did show optimal sensitivity and specificity for combined immunohistochemistry, but their conclusions were limited by the low number of proven FH germline mutations carriers (n = 9, vs. 24 in this study). Like us, they observed that FH-deficient renal cell carcinomas were complex and made of several distinct patterns. But again, the number of proven mutation carriers was low. Furthermore, they did not report renal cell carcinoma detailed morphological patterns in proven non-carriers, while we reviewed 12 type 2 papillary renal cell carcinomas from wild-type patients. Finally, one of our cases presented three FH−/2SC+ unilocular cysts in the renal parenchyma adjacent to a renal cell carcinoma (Fig. 4a-c) , confirming observations already made in a mouse model and in two hereditary leiomyomatosis and renal cell carcinoma cases [5, 6, 22] . The hypothesis is that cysts act as precursor lesions, although the pathogenesis of the malignant transformation remains unclear.
In conclusion, our study shows that prominent eosinophilic nucleoli with perinucleolar halos are not a distinctive feature of hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma, as they are often seen in type 2 papillary renal cell carcinoma from patients with no FH germline mutation. Both ISUP and WHO renal cell carcinoma classification should be revised accordingly. Multiple growth patterns in renal cell carcinoma, in particular rhabdoid and sarcomatoid, and combined FH−/2SC+ immunohistochemistries are crucial in identifying which patients should be referred to Cancer Genetics clinics for genetic counseling and germline analysis. One must always keep in mind the benefits of identifying a FH mutation, i.e., targeted testing in relatives and subsequent yearly renal cell carcinoma screening in carriers, with the aim of diagnosing potentially life-threatening tumors before it is too late.
